摘要
卵巢癌病死率高居妇科三大恶性肿瘤之首,目前标准的治疗方案是根治性手术联合铂类辅助化疗。虽然卵巢癌的治疗在生物技术方面取得了很大进展,但大部分患者仍会出现耐药及复发。近年来研究表明,肿瘤干细胞(CSC)是肿瘤耐药和复发的根源,因此从CSC出发可为临床治疗卵巢癌提供新的研究方向。目前,卵巢癌干细胞的鉴定及分离均取得了很大进步,在抗卵巢癌的治疗中,通过对卵巢癌干细胞相关分子标志物及信号转导通路的深入研究已经成功引进了新的治疗方法。
Ovarian cancer mortality is currently the top among three gynecological malignancies,and radical surgery combined with platinum-based adjuvant chemotherapy is the standard treatment now. Although there have been encouraging developments in biotechnology,most patients develop resistance and relapse. In recent years,studies have shown that cancer stem cells are the root of tumor resistance and relapse. Therefore,starting from cancer stem cells,may provide a new research direction for radical cure of ovarian cancer. Now the identification and isolation of ovarian cancer stem cells have made great progress. In the treatment of ovarian cancer,new treatments have been successfully introduced through in-depth study of ovarian cancer stem cell related molecular markers and signal transduction pathways.
出处
《医学综述》
2018年第3期497-501,共5页
Medical Recapitulate
关键词
卵巢癌
肿瘤干细胞
表面标志物
信号通路
靶向治疗
Ovarian cancer
Cancer stem cells
Surface marker
Signal path
Targeted therapy
